Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN) (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (SOPH) (Nasdaq ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk ...
The National Institutes of Health established the Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium in 2021 with the goal of finding molecular diagnoses for individuals ...
Opportunities in the Molecular Biology Enzymes Reagents and Kits market include rising R&D investments and growing demand for ...
The point-of-care (POC) molecular diagnostics market is steadily expanding, with a compound annual growth rate (CAGR) of approximately 6%. This growth is fueled by a growing need for fast, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback